-
Numit 5% Cream
Numit 5% Cream
Numit Numbing cream is a topical anaesthetic cream that provides anaesthesia of the skin.
Numit numbing cream Proudly Australian made and owned by Ego, the experts in skincare. Numit cream was first manufactured in 2017 by Ego Pharmaceuticals to provide an affordable topical anaesthetic option for minor procedures, vaccinations and needles, tattoo sessions and removal and minor superficial cosmetic procedures. Numit is manufactured in Melbourne, Australia in our state-of-the-art facility and to Australia’s high manufacturing standards for our Australian community.
Is a fear of needles holding you back? Numit numbing cream can provide at least 2 hours of anaesthesia to help you face vaccinations, blood tests and minor cosmetic procedures.
Numit contains a harmonious combination of lidocaine 2.5% w/w (also called lignocaine) and prilocaine 2.5% w/w. Studies have shown that this combination of local anaesthetics can penetrate the skin and target nerve endings. This helps stop pain signals from starting and spreading1,2 and creates a skin-numbing effect.
Droplets of liquid anaesthetic penetrate the skin to numb the site. These droplets also form a ‘reservoir’ in the top layer of skin5.
The reservoir continues to release anaesthetic into the skin’s deeper layers, which increases the numbing effect for up to 60 minutes after the cream is removed6*.
1. NIH. National Cancer Institutes SEER training modules [internet]. 2018 [cited 2018 May 1]. Available from https://training.seer.cancer.gov/melanoma/anatomy/layers.html
2. Bjerring P, Arendt-Nielsen L. Depth and duration of skin analgesia to needle insertion after topical application of Emla cream. Br J Anaesth 1990; 64(2):173–7.
3. NIH. National Cancer Institutes SEER training modules [internet]. 2018 [cited 2018 May 1]. Available from https://training.seer.cancer.gov/melanoma/anatomy/layers.html
4. Bjerring P, Arendt-Nielsen L. Depth and duration of skin analgesia to needle insertion after topical application of Emla cream. Br J Anaesth 1990; 64(2):173–7.
5. Tadicherla S, Berman B. Percutaneous dermal drug delivery for local pain control. Ther Clin Risk Manag 2006;2(1):99-113.
6. Data held on file at Ego Pharmaceuticals Pty Ltd.
*Only relevant for application time under occlusion of 1 hour
